A randomized controlled trial of a novel AI-based prognostic decision support tool integrated into the electronic health record for ischemic heart disease: Rationale and design of the PM Heart trial
Study context
- Population
- Hospitalized patients with coronary artery disease at the cardiology departments in The Capital Region and Region Zealand in Denmark
- Planned comparison
- clinical use of the prognosis calculated by the algorithm, compared to standard of care
- Primary endpoint
- Composite outcome:
- Consisting of re-admissions within 30 days
- One-year survival rates after randomization
- Follow-up
- 30 days and one year after randomization
Methodological detailsrandomized (1:1 ratio) immediately after coronary angiography, automatically enrolling and randomizing
- Randomized (1:1 ratio) immediately after coronary angiography
- Automatically enrolling and randomizing
No results yet. This paper sets out the design of a trial; its results are to come.
Further findings
Trial conduct
- Inclusion began September 2023, and follow-up is expected to finish in 2026
- Design paper; no results reported
Original publication
A randomized controlled trial of a novel AI-based prognostic decision support tool integrated into the electronic health record for ischemic heart disease: Rationale and design of the PM Heart trial. Am Heart J. Published 18 October 2026. doi:10.
Summarised from the published abstract; every number is checked against it